Bio Medica Laboratories Limited, incorporated on August 14, 2015, originally operated as a private limited company before transitioning to public status on October 24, 2024. It specializes in the manufacturing of pharmaceutical parenteral formulations and produces a wide range of injectable drugs, including Liquid Injections and Dry Powder Injections. The company's portfolio spans ethical drugs, generics, and over-the-counter (OTC) products, catering to both human and veterinary healthcare needs. These injectables are available in single and multi-dose forms.
The company operates under a B2B contract manufacturing model and does not sell directly to end consumers. Instead, it partners with other pharmaceutical companies to produce specialized formulations based on custom requirements. Bio Medica enters into agreements allowing its partners to brand the products with their own names as "marketed by" or "Technical Collaborator," while maintaining its role as the manufacturer on the product's packaging.
To fund its expansion, Bio Medica Laboratories Limited is planning a public issue of 37,71,600 equity shares, each with a face value of Rs 10. This includes a fresh issuance of 33,94,800 equity shares and 3,76,800 equity shares offered for sale. This upcoming public issue provides an opportunity for investors to engage with a growing pharmaceutical manufacturer focused on offering tailored, high-quality injectable solutions to its clientele.